Millendo Therapeutics
closedAtterocor focuses on research and development of therapeutics for adrenal disease.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD164—245m (Dealroom.co estimates Aug 2018.)
Company register number 497575621
Ann Arbor Michigan (HQ), Écully Auvergne-Rhône-Alpes (founding location)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$16.0m | Series A | ||
N/A | $8.5m | Growth Equity VC | |
$62.0m | Series B | ||
$30.0m | Late VC | ||
N/A | Merger | ||
Total Funding | CAD159m |
Recent News about Millendo Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Millendo Therapeutics
EditACQUISITION by AstraZeneca Mar 2024
ACQUISITION by Millendo Therapeutics Aug 2018
exited